Immunovant Reports $505.6M Annual Loss, Prepares Brepocitinib Launch
IMVT has more than doubled off its 52-week low of $13.79 on elevated volume (12× avg).
Summary
Immunovant reported a $505.6 million net loss for fiscal year 2026, primarily driven by increased R&D for its IMVT-1402 program. This financial update follows the company's 10-K filing yesterday, which also detailed strong preliminary clinical results for IMVT-1402. Despite the loss, Immunovant holds $902.1 million in cash, projected to fund operations through the potential IMVT-1402 launch. The company is also advancing its brepocitinib program, preparing for commercial launch in dermatomyositis.
At the time of this announcement, IMVT was trading at $35.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2B. The 52-week trading range was $13.79 to $36.29. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.